Cor Therapeutics Inc. announced on Tuesday that it hasreceived a grant for up to $500,000 from the National Heart,Lung and Blood Institute to support preclinical evaluation anddevelopment of recombinant factor Xai, an anti-thromboticagent.

Research under the Phase II small business innovationresearch grant will focus on the production of factor rXai andtesting of its anti-thrombotic activity in animal models. Cor(NASDAQ:CORR) will evaluate the factor for arterial as well asvenous applications, according to Laura Brege, vice presidentand chief financial officer.

The South San Francisco, Calif., company has demonstrated thatfactor rXai blocks thrombin synthesis, a critical event in theclotting process, and subsequent clot formation. Cor said it hasalso shown in animal models that factor Xai inhibits venousthrombosis without significantly affecting systemic clottingtimes. Diseases associated with venous thrombosis include deepvein thrombosis and pulmonary embolism.

Cor shares closed unchanged at $11.50. -- SU

(c) 1997 American Health Consultants. All rights reserved.